Following further studies for Rezum treatment for BPH with the Rezum II Study, NICE have published the next steps in their medical technologies guidance on the use of Rezum and it's impact on the NHS. Key points from this report highlight the durability and cost benefits associated with Rezum implementation and include:
- Rezum should be used for men with moderate to severe LUTS with an estimated prostate volume of 30 cm3to 80 cm3
- Quality of life is an important outcome when considering patient benefit
- The rate of surgical reintervention is low with Rezum
- Rezum is a day surgery procedure that can be done under local anaesthetic with sedation but it may not be suitable for everyone
- Carrying out Rezum as day surgery is the main driver for cost savings
- Rezum is cost saving when compared to standard treatments such as TURP and HoLEP.
Professor Richard Hindley has been instrumental in the collation of data from his Rezum patients and engaging with NICE as an expert adviser. Having now performed over 600 Rezum cases, we continue to audit our patients and collect data to support the efficacy of this treatment as an option for our patients with BPH.